Lee Seung-Tae, Neelapu Sattva S, Kwak Larry W
Department of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Yonsei Med J. 2007 Feb 28;48(1):1-10. doi: 10.3349/ymj.2007.48.1.1.
The unique antigenic determinants (Idiotype [Id]) of the immunoglobulin expressed on a given B-cell malignancy can serve as a tumor-specific antigen for active immunotherapy. Therapeutic vaccines targeting the tumor-specific idiotype have demonstrated promising results against lymphomas in phase I/II studies and are currently being evaluated in phase III randomized trials. Additional vaccine therapies being developed include those based on DNA, dendritic cells, gene-modified tumor cells. It is hoped that immunotherapeutic agents, used in tandem or in combination, may in the future allow effective treatment of lymphoid malignancies and delay or even replace the need for conventional cytotoxic therapies.
特定B细胞恶性肿瘤所表达免疫球蛋白的独特抗原决定簇（独特型[Id]）可作为主动免疫治疗的肿瘤特异性抗原。在I/II期研究中，针对肿瘤特异性独特型的治疗性疫苗已显示出对淋巴瘤有前景良好的效果，目前正在III期随机试验中进行评估。正在研发的其他疫苗疗法包括基于DNA、树突状细胞、基因修饰肿瘤细胞的疗法。人们希望，串联或联合使用免疫治疗药物，未来可能实现对淋巴恶性肿瘤的有效治疗，并推迟甚至取代传统细胞毒性疗法的需求。
